Pictet Asset Management Holding SA Sells 94,852 Shares of Enliven Therapeutics, Inc. $ELVN

Key Points

• Pictet Asset Management Holding SA reduced its stake in Enliven Therapeutics by 6.8%, selling 94,852 shares in Q4 and now holds 1,303,235 shares (about 2.20% of the company) valued at roughly $20.07 million per its 13F filing.
• Enliven is a clinical‑stage biotech with a market cap of $2.54 billion; shares trade between a 52‑week low/high of $14.78/$48.53 (50‑day/200‑day SMAs $36.23/$26.83) and the company recently missed quarterly EPS, reporting -$0.48 versus a -$0.42 estimate.
• Analysts collectively give a Moderate Buy rating (five Buys, one Sell) with a consensus price target of $43.40, while insiders have sold about 16,230 shares in the last 90 days but still own 25.90% of the stock.

Pictet Asset Management Holding SA lessened its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 6.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,303,235 shares of the company's stock after selling 94,852 shares during the period. Pictet Asset Management Holding SA owned 2.20% of Enliven Therapeutics worth $20,070,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Commodore Capital LP increased its stake in shares of Enliven Therapeutics by 0.4% in the 2nd quarter. Commodore Capital LP now owns 4,692,809 shares of the company's stock valued at $94,138,000 after buying an additional 17,809 shares during the period. Polar Capital Holdings Plc lifted its stake in shares of Enliven Therapeutics by 1.5% during the third quarter. Polar Capital Holdings Plc now owns 3,095,007 shares of the company's stock valued at $63,355,000 after acquiring an additional 44,713 shares during the period. Vanguard Group Inc. boosted its holdings in Enliven Therapeutics by 5.9% in the third quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company's stock valued at $52,260,000 after acquiring an additional 142,378 shares during the last quarter. Vestal Point Capital LP increased its position in Enliven Therapeutics by 364.0% in the third quarter. Vestal Point Capital LP now owns 1,160,000 shares of the company's stock worth $23,745,000 after purchasing an additional 910,000 shares during the period. Finally, Duquesne Family Office LLC increased its position in Enliven Therapeutics by 104.6% in the third quarter. Duquesne Family Office LLC now owns 947,405 shares of the company's stock worth $19,393,000 after purchasing an additional 484,405 shares during the period. 95.08% of the stock is currently owned by institutional investors.

Enliven Therapeutics Price Performance

Shares of NASDAQ:ELVN opened at $41.70 on Friday. The firm's 50 day simple moving average is $36.23 and its 200 day simple moving average is $26.83. Enliven Therapeutics, Inc. has a fifty-two week low of $14.78 and a fifty-two week high of $48.53. The company has a market capitalization of $2.54 billion, a price-to-earnings ratio of -22.42 and a beta of 0.32.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its earnings results on Tuesday, March 3rd. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.06). Equities research analysts expect that Enliven Therapeutics, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Enliven Therapeutics in a research report on Monday, April 20th. Mizuho boosted their price target on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the stock an "outperform" rating in a research note on Wednesday, March 25th. Wall Street Zen upgraded shares of Enliven Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, April 25th. Finally, HC Wainwright lifted their target price on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the stock a "buy" rating in a report on Thursday, March 26th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Enliven Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $43.40.

Insiders Place Their Bets

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 5,000 shares of the stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $29.04, for a total value of $145,200.00. Following the completion of the sale, the insider directly owned 740,188 shares in the company, valued at $21,495,059.52. This represents a 0.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard A. Heyman sold 1,230 shares of the firm's stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $26.18, for a total value of $32,201.40. Following the sale, the director directly owned 22,647 shares in the company, valued at approximately $592,898.46. This represents a 5.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 16,230 shares of company stock worth $473,201. Corporate insiders own 25.90% of the company's stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.